MedTrace Logo

NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01654250 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2016-02-03

Study results available
· View outcomes & findings →

Summary

The safety and efficacy of a chewable formulation of extended-release methylphenidate will be studied in children with ADHD

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

DRUG

NWP09

Methylphenidate, variable dose, daily dosing, 1 week duration

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01654250 on ClinicalTrials.gov